Key facts
- It has raised $500K across 1 recorded rounds; the latest was Seed Round ($500K) in Oct 2023.
- Oncobiomix has filed 4 Form Ds with the SEC since 2023, most recently Sep 2025 ($500K sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Oncobiomix
Funding rounds
1 roundsAbout Oncobiomix
Developer of diagnostic technologies designed for microbiome-based health monitoring. The company's platform integrates artificial intelligence-powered microbial signature analysis, sample collection kits, and laboratory sequencing workflows, enabling clinical researchers and healthcare practitioners to access tools that support early disease detection, health insights, and improved understanding of microbiome-related conditions across diverse patient populations.
- Sector
- Healthcare
- HQ
- San Antonio, TX, United States
- Founded
- 2023
- Employees
- 2
- Website
- oncobiomix.com/
- Ownership
- Privately Held (backing)
Oncobiomix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oncobiomix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oncobiomix in its N-PORT filings yet. We sweep new filings monthly.